Based on the Defence Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Defence Therapeutics Inc is not available over the next 12 months. Defence Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Defence Therapeutics Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Defence Therapeutics Inc’s stock price was CAD 0.60. Defence Therapeutics Inc’s stock price has changed by -7.69% over the past week, +11.11% over the past month and -72.48% over the last year.
No recent analyst target price found for Defence Therapeutics Inc
No recent average analyst rating found for Defence Therapeutics Inc
Company Overview Defence Therapeutics Inc
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. It also offers Accuvac for dendritic cell cancer vaccines; a protein-based vaccine formulation against COVID and infectious diseases; and cervical cancer vaccine. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Vancouver, Canada. Read Less
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, ...Read More
Frequently Asked Questions About Defence Therapeutics Inc (DTC:CA) Stock
Stock Target Advisor's fundamental analysis for Defence Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on DTC:CA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on DTC:CA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on DTC:CA's stock to indicate if its overvalued.
The last closing price of DTC:CA's stock was CAD 0.60.
The most recent market capitalization for DTC:CA is CAD 0.03B.
Unfortunately we do not have enough analyst data on DTC:CA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Defence Therapeutics Inc's stock.
As per our most recent records Defence Therapeutics Inc has 0 Employees.
Defence Therapeutics Inc's registered address is 1680 ? 200 Burrard Street, Vancouver, BC, Canada, V6C 3L6.
You can get more information about it from Defence Therapeutics Inc's website at https://defencetherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Defence Therapeutics Inc (DTC:CA) Stock
Stock Target Advisor's fundamental analysis for Defence Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on DTC:CA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on DTC:CA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on DTC:CA's stock to indicate if its overvalued.
The last closing price of DTC:CA's stock was CAD 0.60.
The most recent market capitalization for DTC:CA is CAD 0.03B.
Unfortunately we do not have enough analyst data on DTC:CA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Defence Therapeutics Inc's stock.
As per our most recent records Defence Therapeutics Inc has 0 Employees.
Defence Therapeutics Inc's registered address is 1680 ? 200 Burrard Street, Vancouver, BC, Canada, V6C 3L6.
You can get more information about it from Defence Therapeutics Inc's website at https://defencetherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DTC:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
